Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use

Journal of Clinical Hypertension

Volumn 11, Issue 12, 2009, Pages 766-768

  Reddy, Kota J ^a   Singh, Manmeet ^a   Batsell, Richard R ^b   Bangit, Joey R ^a   Zaheer, Misbah S ^a   John, Shirley ^a   Varghese, Shajan ^a   Molinella, Ronald ^a  

^a Reddy Cardiac Wellness   (United States)

^b RICE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; COLESEVELAM; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; MYALGIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ALLYLAMINE; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL, LDL; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; PULSE THERAPY, DRUG; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 70849126674     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1559-4572.2009.00055.x     Document Type: Article

References (6)

1. Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R. Efficacy and safety of rosuvastatin every other day compared with once in patients with hypercholesterolemia. Ann Pharmacother 2006, 40:1917-1923.
2. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin twice a week in patients intolerant to daily statins. Am J Cardiol 2008, 101:1747-1748.
3. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003, 107(25):3124-3128.
4. Mauro VF, Tuckerman CE. Ezetimibe for management of hypercholesterolemia. Ann Pharmacother 2003, 37(6):839-848.
5. Kastelein JJ. The future of lipid-lowering therapy: the big picture. Neth J Med 2003, 61(suppl 5):35-39.
6. Weston C. Place of ezetimibe in clinical practice. Hosp Med 2003, 64(8):473-478.